{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T23:03:07Z","timestamp":1789858987739,"version":"4.0.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,19]]},"DOI":"10.7759\/cureus.116558","type":"journal-article","created":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T22:38:32Z","timestamp":1789857512000},"source":"Crossref","is-referenced-by-count":0,"title":["Thyroid Eye Disease in the Teprotumumab Era: A Narrative Review of Expanding the Therapeutic Window Beyond Disease Activity"],"prefix":"10.7759","author":[{"given":"Zubaida","family":"Sirang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raisa","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wardah","family":"Moazzum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irfan","family":"Jeeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000002467","article-title":"Thyroid eye disease: epidemiology, natural history, and risk factors","volume":"39","author":"Bartalena L","year":"2023","unstructured":"Bartalena L, Gallo D, Tanda ML, Kahaly GJ. Thyroid eye disease: epidemiology, natural history, and risk factors. Ophthalmic Plast Reconstr Surg. 2023, 39:S2-8. 10.1097\/IOP.0000000000002467","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(25)00066-X","article-title":"Thyroid eye disease (Graves\u2019 orbitopathy): clinical presentation, epidemiology, pathogenesis, and management","volume":"13","author":"Wiersinga WM","year":"2025","unstructured":"Wiersinga WM, Eckstein AK, \u017darkovi\u0107 M. Thyroid eye disease (Graves\u2019 orbitopathy): clinical presentation, epidemiology, pathogenesis, and management. Lancet Diabetes Endocrinol. 2025, 13:600-14. 10.1016\/S2213-8587(25)00066-X","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s40662-014-0009-8","article-title":"An overview of thyroid eye disease","volume":"1","author":"McAlinden C","year":"2014","unstructured":"McAlinden C. An overview of thyroid eye disease. Eye Vis (Lond). 2014, 1:9. 10.1186\/s40662-014-0009-8","journal-title":"Eye Vis (Lond)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1996.8220832.x","article-title":"Smoking and endocrine ophthalmopathy: impact of smoking severity and current vs lifetime cigarette consumption","volume":"45","author":"Pfeilschifter J","year":"1996","unstructured":"Pfeilschifter J, Ziegler R. Smoking and endocrine ophthalmopathy: impact of smoking severity and current vs lifetime cigarette consumption. Clin Endocrinol (Oxf). 1996, 45:477-81. 10.1046\/j.1365-2265.1996.8220832.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000002555","article-title":"Dysthyroid optic neuropathy","volume":"39","author":"Potvin AR","year":"2023","unstructured":"Potvin AR, Pakdel F, Saeed P. Dysthyroid optic neuropathy. Ophthalmic Plast Reconstr Surg. 2023, 39:S65-80. 10.1097\/IOP.0000000000002555","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.08.030","article-title":"The psychosocial and clinical outcomes of orbital decompression surgery for thyroid eye disease and predictors of change in quality of life","volume":"122","author":"Wickwar S","year":"2015","unstructured":"Wickwar S, McBain H, Ezra DG, Hirani SP, Rose GE, Newman SP. The psychosocial and clinical outcomes of orbital decompression surgery for thyroid eye disease and predictors of change in quality of life. Ophthalmology. 2015, 122:2568-76.e1. 10.1016\/j.ophtha.2015.08.030","journal-title":"Ophthalmology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.82.7.773","article-title":"Development of a disease specific quality of life questionnaire for patients with Graves' ophthalmopathy: the GO-QOL","volume":"82","author":"Terwee CB","year":"1998","unstructured":"Terwee CB, Gerding MN, Dekker FW, Prummel MF, Wiersinga WM. Development of a disease specific quality of life questionnaire for patients with Graves' ophthalmopathy: the GO-QOL. Br J Ophthalmol. 1998, 82:773-9. 10.1136\/bjo.82.7.773","journal-title":"Br J Ophthalmol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2015-307399","article-title":"Pathogenesis of thyroid eye disease: review and update on molecular mechanisms","volume":"100","author":"Khong JJ","year":"2016","unstructured":"Khong JJ, McNab AA, Ebeling PR, Craig JE, Selva D. Pathogenesis of thyroid eye disease: review and update on molecular mechanisms. Br J Ophthalmol. 2016, 100:142-50. 10.1136\/bjophthalmol-2015-307399","journal-title":"Br J Ophthalmol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1210\/er.2018-00066","article-title":"Insulin-like growth factor-I receptor and thyroid-associated ophthalmopathy","volume":"40","author":"Smith TJ","year":"2019","unstructured":"Smith TJ, Janssen JA. Insulin-like growth factor-I receptor and thyroid-associated ophthalmopathy. Endocr Rev. 2019, 40:236-67. 10.1210\/er.2018-00066","journal-title":"Endocr Rev"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith TJ","year":"2017","unstructured":"Smith TJ, Kahaly GJ, Ezra DG, et al.. Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med. 2017, 376:1748-61. 10.1056\/NEJMoa1614949","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad637","article-title":"Efficacy and safety of teprotumumab in patients with thyroid eye disease of long duration and low disease activity","volume":"109","author":"Douglas RS","year":"2023","unstructured":"Douglas RS, Couch S, Wester ST, et al.. Efficacy and safety of teprotumumab in patients with thyroid eye disease of long duration and low disease activity. J Clin Endocrinol Metab. 2023, 109:25-35. 10.1210\/clinem\/dgad637","journal-title":"J Clin Endocrinol Metab"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.10.017","article-title":"Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and re-treatment: OPTIC-X study","volume":"129","author":"Douglas RS","year":"2022","unstructured":"Douglas RS, Kahaly GJ, Ugradar S, et al.. Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and re-treatment: OPTIC-X study. Ophthalmology. 2022, 129:438-49. 10.1016\/j.ophtha.2021.10.017","journal-title":"Ophthalmology"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2026.04.022","article-title":"THRIVE: a phase 3, randomized, double-masked, placebo-controlled study of veligrotug for active thyroid eye disease","volume":"133","author":"Yen MT","year":"2026","unstructured":"Yen MT, Cockerham K, Saeed P, et al.. THRIVE: a phase 3, randomized, double-masked, placebo-controlled study of veligrotug for active thyroid eye disease. Ophthalmology. 2026, 133:1085-96. 10.1016\/j.ophtha.2026.04.022","journal-title":"Ophthalmology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-018-0285-y","article-title":"B cells in Graves' orbitopathy: more than just a source of antibodies?","volume":"33","author":"Salvi M","year":"2019","unstructured":"Salvi M, Covelli D. B cells in Graves' orbitopathy: more than just a source of antibodies?. Eye (Lond). 2019, 33:230-4. 10.1038\/s41433-018-0285-y","journal-title":"Eye (Lond)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.73.8.639","article-title":"Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach","volume":"73","author":"Mourits MP","year":"1989","unstructured":"Mourits MP, Koornneef L, Wiersinga WM, Prummel MF, Berghout A, van der Gaag R. Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach. Br J Ophthalmol. 1989, 73:639-44. 10.1136\/bjo.73.8.639","journal-title":"Br J Ophthalmol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy","volume":"185","author":"Bartalena L","year":"2021","unstructured":"Bartalena L, Kahaly GJ, Baldeschi L, et al.. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy. Eur J Endocrinol. 2021, 185:G43-67. 10.1530\/EJE-21-0479","journal-title":"Eur J Endocrinol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2022.0251","article-title":"Management of thyroid eye disease: a consensus statement by the American Thyroid Association and the European Thyroid Association","volume":"32","author":"Burch HB","year":"2022","unstructured":"Burch HB, Perros P, Bednarczuk T, et al.. Management of thyroid eye disease: a consensus statement by the American Thyroid Association and the European Thyroid Association. Thyroid. 2022, 32:1439-70. 10.1089\/thy.2022.0251","journal-title":"Thyroid"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2011.11.007","article-title":"Evaluating Graves' orbitopathy","volume":"26","author":"Dolman PJ","year":"2012","unstructured":"Dolman PJ. Evaluating Graves' orbitopathy. Best Pract Res Clin Endocrinol Metab. 2012, 26:229-48. 10.1016\/j.beem.2011.11.007","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1012985","article-title":"Selenium and the course of mild Graves' orbitopathy","volume":"364","author":"Marcocci C","year":"2011","unstructured":"Marcocci C, Kahaly GJ, Krassas GE, et al.. Selenium and the course of mild Graves' orbitopathy. N Engl J Med. 2011, 364:1920-31. 10.1056\/NEJMoa1012985","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s42000-019-00133-5","article-title":"Challenges and perspectives of selenium supplementation in Graves' disease and orbitopathy","volume":"19","author":"Bednarczuk T","year":"2020","unstructured":"Bednarczuk T, Schomburg L. Challenges and perspectives of selenium supplementation in Graves' disease and orbitopathy. Hormones (Athens). 2020, 19:31-9. 10.1007\/s42000-019-00133-5","journal-title":"Hormones (Athens)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30020-2","article-title":"Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves\u2019 orbitopathy (MINGO): a randomised, observer-masked, multicentre trial","volume":"6","author":"Kahaly GJ","year":"2018","unstructured":"Kahaly GJ, Riedl M, K\u00f6nig J, et al.. Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves\u2019 orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. Lancet Diabetes Endocrinol. 2018, 6:287-98. 10.1016\/S2213-8587(18)30020-2","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the treatment of active thyroid eye disease","volume":"382","author":"Douglas RS","year":"2020","unstructured":"Douglas RS, Kahaly GJ, Patel A, et al.. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020, 382:341-52. 10.1056\/NEJMoa1910434","journal-title":"N Engl J Med"},{"key":"ref23","unstructured":"Highlights of Prescribing Information. (2025). https.\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761143s032lbl.pdf."},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-021-01539-5","article-title":"Teprotumumab for thyroid eye disease: early response is not required for benefit","volume":"36","author":"Ugradar S","year":"2022","unstructured":"Ugradar S, Wang Y, Mester T, Kahaly GJ, Douglas RS. Teprotumumab for thyroid eye disease: early response is not required for benefit. Eye (Lond). 2022, 36:1403-8. 10.1038\/s41433-021-01539-5","journal-title":"Eye (Lond)"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2024.07.018","article-title":"The rate of re-treatment in patients treated with teprotumumab: a multicenter study of 119 patients with 1 year of follow-up","volume":"132","author":"Ugradar S","year":"2025","unstructured":"Ugradar S, Parunakian E, Malkhasyan E, et al.. The rate of re-treatment in patients treated with teprotumumab: a multicenter study of 119 patients with 1 year of follow-up. Ophthalmology. 2025, 132:92-7. 10.1016\/j.ophtha.2024.07.018","journal-title":"Ophthalmology"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2023.0656","article-title":"Long-term efficacy of teprotumumab in thyroid eye disease: follow-up outcomes in three clinical trials","volume":"34","author":"Kahaly GJ","year":"2024","unstructured":"Kahaly GJ, Subramanian PS, Conrad E, Holt RJ, Smith TJ. Long-term efficacy of teprotumumab in thyroid eye disease: follow-up outcomes in three clinical trials. Thyroid. 2024, 34:880-9. 10.1089\/thy.2023.0656","journal-title":"Thyroid"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000002531","article-title":"Proptosis regression after teprotumumab treatment for thyroid eye disease","volume":"40","author":"Rosenblatt TR","year":"2024","unstructured":"Rosenblatt TR, Chiou CA, Yoon MK, Wolkow N, Lee NG, Freitag SK. Proptosis regression after teprotumumab treatment for thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2024, 40:187-91. 10.1097\/IOP.0000000000002531","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000003197","article-title":"Extended long-term follow-up of proptosis regression after teprotumumab treatment for thyroid eye disease","volume":"42","author":"Rosenblatt TR","year":"2026","unstructured":"Rosenblatt TR, Chiou CA, Yoon MK, Lee NG, Wolkow N, Freitag SK. Extended long-term follow-up of proptosis regression after teprotumumab treatment for thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2026, 42:564-9. 10.1097\/IOP.0000000000003197","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1097\/WNO.0000000000001560","article-title":"Expert consensus on the use of teprotumumab for the management of thyroid eye disease using a modified-Delphi approach","volume":"42","author":"Douglas RS","year":"2022","unstructured":"Douglas RS, Kossler AL, Abrams J, et al.. Expert consensus on the use of teprotumumab for the management of thyroid eye disease using a modified-Delphi approach. J Neuroophthalmol. 2022, 42:334-9. 10.1097\/WNO.0000000000001560","journal-title":"J Neuroophthalmol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2024.01.023","article-title":"Glycemic trends in patients with thyroid eye disease treated with teprotumumab in 3 clinical trials","volume":"131","author":"Smith TJ","year":"2024","unstructured":"Smith TJ, Cavida D, Hsu K, et al.. Glycemic trends in patients with thyroid eye disease treated with teprotumumab in 3 clinical trials. Ophthalmology. 2024, 131:815-26. 10.1016\/j.ophtha.2024.01.023","journal-title":"Ophthalmology"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2023.0466","article-title":"A prospective study examining audiometry outcomes following teprotumumab treatment for thyroid eye disease","volume":"34","author":"Douglas RS","year":"2024","unstructured":"Douglas RS, Parunakian E, Tolentino J, Malkhasyan E, Geng J, Sherman M, Ugradar S. A prospective study examining audiometry outcomes following teprotumumab treatment for thyroid eye disease. Thyroid. 2024, 34:134-7. 10.1089\/thy.2023.0466","journal-title":"Thyroid"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000003126","article-title":"Longitudinal glycemic outcomes in patients with thyroid eye disease treated with teprotumumab","volume":"42","author":"Ha SK","year":"2026","unstructured":"Ha SK, Lin LY, Chiou CA, Wolkow N, Lee NG, Yoon MK, Freitag SK. Longitudinal glycemic outcomes in patients with thyroid eye disease treated with teprotumumab. Ophthalmic Plast Reconstr Surg. 2026, 42:397-403. 10.1097\/IOP.0000000000003126","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2018.07.038","article-title":"Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant Graves orbitopathy: a randomized clinical trial","volume":"195","author":"Perez-Moreiras JV","year":"2018","unstructured":"Perez-Moreiras JV, Gomez-Reino JJ, Maneiro JR, et al..  Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant Graves orbitopathy: a randomized clinical trial. Am J Ophthalmol. 2018, 195:181-90. 10.1016\/j.ajo.2018.07.038","journal-title":"Am J Ophthalmol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012984.pub2","article-title":"Tocilizumab for thyroid eye disease","volume":"11","author":"Hamed Azzam S","year":"2018","unstructured":"Hamed Azzam S, Kang S, Salvi M, Ezra DG. Tocilizumab for thyroid eye disease. Cochrane Database Syst Rev. 2018, 11:CD012984. 10.1002\/14651858.CD012984.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3109\/01658107.2015.1039140","article-title":"Rituximab in the treatment of thyroid eye disease: a review","volume":"39","author":"Ostrowski RA","year":"2015","unstructured":"Ostrowski RA, Bussey MR, Shayesteh Y, Jay WM. Rituximab in the treatment of thyroid eye disease: a review. Neuroophthalmology. 2015, 39:109-15. 10.3109\/01658107.2015.1039140","journal-title":"Neuroophthalmology"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.10.025","article-title":"Orbital radiation for thyroid eye disease: a report by the American Academy of Ophthalmology","volume":"129","author":"Sobel RK","year":"2022","unstructured":"Sobel RK, Aakalu VK, Vagefi MR, et al.. Orbital radiation for thyroid eye disease: a report by the American Academy of Ophthalmology. Ophthalmology. 2022, 129:450-5. 10.1016\/j.ophtha.2021.10.025","journal-title":"Ophthalmology"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.4103\/ijo.IJO_719_22","article-title":"Dysthyroid optic neuropathy: demographics, risk factors, investigations, and management outcomes","volume":"70","author":"Poonam NS","year":"2022","unstructured":"Poonam NS, Alam MS, Oberoi P, Mukherjee B. Dysthyroid optic neuropathy: demographics, risk factors, investigations, and management outcomes. Indian J Ophthalmol. 2022, 70:4419-26. 10.4103\/ijo.IJO_719_22","journal-title":"Indian J Ophthalmol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2022.02.001","article-title":"Ocular surface disease in thyroid eye disease: a narrative review","volume":"24","author":"Rana HS","year":"2022","unstructured":"Rana HS, Akella SS, Clabeaux CE, Skurski ZP, Aakalu VK. Ocular surface disease in thyroid eye disease: a narrative review. Ocul Surf. 2022, 24:67-73. 10.1016\/j.jtos.2022.02.001","journal-title":"Ocul Surf"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/440015-thyroid-eye-disease-in-the-teprotumumab-era-a-narrative-review-of-expanding-the-therapeutic-window-beyond-disease-activity","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T22:38:35Z","timestamp":1789857515000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/440015-thyroid-eye-disease-in-the-teprotumumab-era-a-narrative-review-of-expanding-the-therapeutic-window-beyond-disease-activity"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,19]]},"references-count":38,"URL":"https:\/\/doi.org\/10.7759\/cureus.116558","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,19]]}}}